Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods

• US 20070141570A1
• Filed: 03/05/2004
• Published: 06/21/2007
• Est. Priority Date: 03/07/2003
• Status: Abandoned Application

• Current Assignee: Sequenom Incorporated (Laboratory Corporation Of America Holdings)
• Original Assignee: Sequenom Incorporated (Laboratory Corporation Of America Holdings)
• Inventors: Kammerer, Stefan, Braun, Andreas
• Application Number:
  US10/548,336
• Publication Number:
  US 20070141570A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/044 Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
• CPC Class Codes: G01N 2800/164 Retinal disorders, e.g. retinopathy
• CPC Class Codes: G01N 2800/28 Neurological disorders
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 33/57496 involving intracellular compounds
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

Polymorphic A-kinase anchor proteins (AKAPs) and nucleic acids encoding the proteins are provided herein. Methods of detecting polymorphic AKAPs and nucleic acids encoding the AKAPs, and kits for use in the detection methods are also provided. Further provided herein are methods of identifying subjects having or at risk of developing diseases or disorders, such as those related to signal transduction and/or cardiovascular disease. Methods of determining susceptibility to morbidity and/or increased or early mortality are also provided.

Claims

1. A method for indicating increased susceptibility of a subject to a disease or disorder, comprising:

conducting an EKG examination;

determining the EKG-PR-interval in the subject, wherein, if the EKG-PR-interval is decreased, then

determining the amino acid present in the subject at position 646 of AKAP10/D-AKAP2 (SEQ ID NO;

2) or the nucleotide present at position corresponding to nucleotide 2073 of SEQ ID NO;

1, wherein the presence of Val at position 646 of SEQ ID NO;

2 or the presence of a -G- at nucleotide position 2073 of SEQ ID NO;

1, indicates increased susceptibility to a disease or disorder.

2. The method of claim 1, wherein the disease or disorder is selected from the group consisting of cardiovascular disorders, cardiac disease, proliferative disorders, neurological disorders, neurodegenerative disorders, obesity, diabetes and peripheral retinopathies.

3. The method of claim 1, wherein the EKG-PR-interval in the subject is compared to a predetermined age-matched standard EKG-PR-interval.

4. The method of claim 3, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control group that is homozygous -AA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or homozygous Ile/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

5. The method of claim 3, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control group that is heterozygous -GA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or heterozygous Val/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

6. The method of claim 3, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control group that is selected from either homozygous -AA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or homozygous Ile/Ile at a position corresponding to position 646 of SEQ ID NO;

2;

or heterozygous -GA- at a position corresponding to nucleotide 2073 of SEQ ID NO;

1 or heterozygous Val/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

7. The method of claim 3, wherein the predetermined standard EKG-PR-interval is obtained from a control age-matched subject without heart disease.

24. The method of claim 1, wherein the disease or disorder is selected from one or more of the group consisting of:

cardiac arrhythmia, brachycardia, atrial fibrillation, sick sinus syndrome, sudden cardiac arrest, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, Wolf-Parkinson-White (WPW) Syndrome, Lown-Ganong-Levin (LGL) Syndrome, hypertension.

25. The method of claim 1, further comprising monitoring the subject for cardiovascular disease.

26. The method of claim 1, further comprising administering to the subject prophylactic steps.

49. The method of claim 1, wherein the amino acid or nucleotide determining step comprises mass spectrometry.

50. The method of claim 1, wherein the amino acid or nucleotide determining step is effected by detecting a signal moiety selected from the group consisting of radioisotopes, enzymes, antigens, antibodies, spectrophotometric reagents, chemiluminescent reagents, fluorescent reagents and other light producing reagents.

51. The method of claim 1, wherein the subject is heterozygous -GA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or heterozygous Val/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

52. The method of claim 1, wherein the subject is homozygous -GG- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or homozygous Val/Val at a position corresponding to position 646 of SEQ ID NO;

2.

8. A method for indicating increased susceptibility of a subject to a disease or disorder associated with the cardiovascular system, comprising:

conducting an EKG exam;

determining the EKG-PR-interval in the subject, wherein, if the EKG-PR-interval is decreased, then

determining the amino acid present at position 646 of AKAP10/D-AKAP2 (SEQ ID NO;

2) or the nucleotide present at position corresponding to nucleotide 2073 of SEQ ID NO;

1, wherein the presence of Val at position 646 of SEQ ID NO;

2 or the presence of a -G- at nucleotide position 2073 of SEQ ID NO;

1, indicates increased susceptibility to a disease or disorder associated with the cardiovascular system.

9. The method of claim 8, wherein the EKG-PR-interval in the subject is compared to a predetermined age-matched standard EKG-PR-interval.

10. The method of claim 9, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control that is homozygous -AA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or homozygous Ile/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

11. The method of claim 9, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control group that is heterozygous -GA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or heterozygous Val/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

12. The method of claim 9, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control group that is selected from either homozygous -AA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or homozygous Ile/Ile at a position corresponding to position 646 of SEQ ID NO;

2;

or heterozygous -GA- at a position corresponding to nucleotide 2073 of SEQ ID NO;

1 or heterozygous Val/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

13. The method of claim 9, wherein the predetermined standard EKG-PR-interval is obtained from a control age-matched subject without heart disease.

14-23. -23. (canceled)

27-29. -29. (canceled)

30. A method for determining responsiveness of a subject to one or more β

-blocking agents, comprising;

detecting for the subject the presence or absence of Val at position 646 of SEQ ID NO;

2 or a -G- nucleotide at a position corresponding to position 2073 of SEQ ID NO;

1, wherein the presence of a Val at position 646 of SEQ ID NO;

2 or a -G- at nucleotide 2073 of SEQ ID NO;

1, is indicative of an increased likelihood that a subject has a modulated response to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

31. The method of claim 30, wherein the modulated response is a decreased response to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

32. The method of claim 31, wherein the decreased response is a non-response to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

33. The method of claim 30, wherein the modulated response is an increased response to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

34. The method of claim 30, wherein at least one β

-blocking agent is an antagonist of a β

-adrenergic receptor.

35. The method of claim 30, wherein at least one β

-blocking agent is an agonist of a β

-adrenergic receptor.

36. A method for determining responsiveness of a subject to one or more β

-blocking agents, comprising;

detecting the presence or absence of Val at position 646 of SEQ ID NO;

2 or a -G- nucleotide at a position corresponding to position 2073 of SEQ ID NO;

1, wherein the presence of a Val at position 646 of SEQ ID NO;

2 or a -G- at nucleotide 2073 of SEQ ID NO;

1, is indicative of an increased likelihood that a subject has an increased response to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

37. The method of claim 36, wherein at least one β

-blocking agent is an antagonist of a β

-adrenergic receptor.

38. The method of claim 36, wherein at least one β

-blocking agent is an agonist of a β

-adrenergic receptor.

39. A method for determining responsiveness of a subject to one or more β

-blocking agents, comprising;

detecting for the subject the presence or absence of Val at position 646 of SEQ ID NO;

2 or a -G- nucleotide at a position corresponding to position 2073 of SEQ ID NO;

1, wherein the presence of a Val at position 646 of SEQ ID NO;

2 or a -G- at nucleotide 2073 of SEQ ID NO;

1, is indicative of an increased likelihood that a subject is non-responsive to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

40. The method of claim 39, wherein at least one β

-blocking agent is an antagonist of a β

-adrenergic receptor.

41. The method of claim 39, wherein at least one β

-blocking agent is an agonist of a β

-adrenergic receptor.

42. A method for determining responsiveness of a subject to one or more β

-blocking agents, comprising;

detecting the presence or absence of Val at position 646 of SEQ ID NO;

2 or a -G- nucleotide at a position corresponding to position 2073 of SEQ ID NO;

1, wherein the presence of a Val at position 646 of SEQ ID NO;

2 or a -G- at nucleotide 2073 of SEQ ID NO;

1, is indicative of an increased likelihood that a subject is hyper-responsive to one or more β

-blocking agents compared to a subject who does not have the allelic variant.

43. The method of claim 42, wherein the β

-blockers is an antagonist of a β

-adrenergic receptor.

44. The method of claim 42, wherein the β

-blockers is an agonist of a β

-adrenergic receptor.

45. A method for indicating susceptibility to morbidity, increased or early mortality, or morbidity and increased or early mortality of a subject;

comprising;

conducting an EKG exam;

determining the EKG-PR-interval in the subject, wherein if the EKG-PR-interval is decreased;

then

determining the amino acid at position 646 of AKAP10/D-AKAP2 (SEQ ID NO;

2) or the nucleotide present at position corresponding to nucleotide 2073 of SEQ ID NO;

1, wherein the presence of Val at position 646 of SEQ ID NO;

2 or the presence of a -G- at nucleotide position 2073 of SEQ ID NO;

1, indicates increased susceptibility to morbidity, increased or early mortality, or morbidity and increased or early mortality of a subject.

46. The method of claim 45, wherein the EKG-PR-interval in the subject is compared to a predetermined standard EKG-PR-interval.

47. The method of claim 46, wherein the predetermined standard EKG-PR-interval is obtained from a known age-matched control that is homozygous -AA- at a position corresponding to nucleotide 2073 of SEQ ID NO:

1 or homozygous Ile/Ile at a position corresponding to position 646 of SEQ ID NO;

2.

48. (canceled)

53. A method for indicating increased susceptibility of a subject to a disease or disorder, comprising:

in a subject determined to have a decreased EKG-PR-interval, determining the amino acid present at position 646 of AKAP10/D-AKAP2 (SEQ ID NO;

2) or the nucleotide present at position corresponding to nucleotide 2073 of SEQ ID NO;

1, wherein the presence of Val at position 646 of SEQ ID NO;

2 or the presence of a -G- at nucleotide position 2073 of SEQ ID NO;

1, indicates increased susceptibility to a disease or disorder.

54-58. -58. (canceled)

60. A method for indicating increased susceptibility of a subject to a disease or disorder, comprising:

conducting an EKG examination;

determining the EKG-PR-interval in the subject, wherein, if the EKG-PR-interval is decreased, then

determining the amino acid present in the subject at position 249 of AKAP10/D-AKAP2 (SEQ ID NO;

2) or the nucleotide present at position corresponding to nucleotide 883 of SEQ ID NO;

1, wherein the presence of His at position 249 of SEQ ID NO;

2 or the presence of a -A- at nucleotide position 883 of SEQ ID NO;

1, indicates increased susceptibility to a disease or disorder.

62. The method of claim 60, wherein the disease or disorder is selected from the group consisting of cardiovascular disorders, cardiac disease, proliferative disorders, neurological disorders, neurodegenerative disorders, obesity, diabetes and peripheral retinopathies.

61. A method for determining responsiveness of a subject to one or more β

-blocking agents, comprising;

detecting for the subject the presence or absence of His at position 249 of SEQ ID NO;

2 or a -A- nucleotide at a position corresponding to position 883 of SEQ ID NO;

1, wherein the presence of a His at position 249 of SEQ ID NO;

2 or a -A- at nucleotide 883 of SEQ ID NO;

1, is indicative of an increased likelihood that a subject has a modulated response to one or more β

-blocking agents compared to a subject who does not have the allelic variant.